首页> 外文期刊>Drugs - Real World Outcomes >A Pilot Study to Assess the Feasibility of a Web-Based Survey to Examine Patient-Reported Symptoms and Satisfaction in Patients with Ankylosing Spondylitis Receiving Secukinumab
【24h】

A Pilot Study to Assess the Feasibility of a Web-Based Survey to Examine Patient-Reported Symptoms and Satisfaction in Patients with Ankylosing Spondylitis Receiving Secukinumab

机译:评估基于网络的调查以检查接受Secukinumab的强直性脊柱炎患者的患者报告的症状和满意度的可行性的初步研究

获取原文
           

摘要

PurposeThis real-world study evaluated the feasibility of assessing patient-reported symptom improvement and treatment satisfaction using a web-based survey among patients with ankylosing spondylitis (AS) treated with secukinumab. MethodsThis cross-sectional, web-based survey collected data on demographics, symptoms, treatment history, and treatment satisfaction from US patients with AS who were receiving secukinumab at survey participation. Patients reported AS symptoms experienced before and after secukinumab initiation, time to symptom improvement, and satisfaction with secukinumab treatment. ResultsOf 2755 patients screened, 200 with AS were included in the analysis. The mean (SD) age of patients was 34.4 (10.6) years; 86.5% were biologic experienced. Most (74.0%) reported overall improvement (“a little,” “moderately,” or “much better”) in AS symptoms since secukinumab initiation compared with before secukinumab initiation; a similar trend was observed for all the individual symptoms analyzed (pain disrupting sleep, fatigue, morning stiffness, pain and stiffness in lower back or neck, sore areas other than joints, and ankle or heel pain [indicating enthesitis]). Approximately 41.9% of patients reported overall symptom improvement within 4?weeks of secukinumab treatment. Most expressed overall satisfaction (“very,” “mostly,” or “somewhat satisfied”) with secukinumab regarding symptom improvement (99.0%), speed of symptom improvement (97.0%), frequency and method of administration (96.0% and 91.5%, respectively), ease of use (93.5%), patient support services (97.0%), and side effects, if any (93.0%). ConclusionMost patients reported overall symptom improvement and satisfaction with treatment. Our study indicates that patient-reported perspectives may be feasibly collected using a web-based survey to provide insights into treatment experience and satisfaction.
机译:目的这项真实世界的研究评估了通过网络调查在经secukinumab治疗的强直性脊柱炎(AS)患者中评估患者报告的症状改善和治疗满意度的可行性。方法:这项基于网络的横断面调查收集了参与调查的接受苏金单抗的美国AS患者的人口统计学,症状,治疗史和治疗满意度的数据。患者报告了苏金单抗治疗前后,出现症状改善的时间以及对苏金单抗治疗的满意程度后出现的AS症状。结果筛选的2755例患者中,有200例患有AS。患者的平均(SD)年龄为34.4(10.6)岁; 86.5%具有生物学经验。大多数患者(74.0%)报告说,自从苏金单抗启动以来,与苏金单抗启动之前相比,AS症状总体改善(“少许”,“中度”或“好得多”);对于所有已分析的个体症状(疼痛破坏睡眠,疲劳,早晨僵硬,下背部或颈部的疼痛和僵硬,关节以外的疮痛区域以及脚踝或脚跟疼痛[表明是脑炎]),观察到类似的趋势。大约41.9%的患者在secukinumab治疗的4周内报告了总体症状改善。大多数人对苏金单抗在症状改善(99.0%),症状改善速度(97.0%),给药频率和给药方法(96.0%和91.5%)上表示总体满意(“非常”,“大多数”或“有些满意”),分别为:易用性(93.5%),患者支持服务(97.0%)和副作用(如果有)(93.0%)。结论大多数患者报告总体症状改善和对治疗的满意度。我们的研究表明,可以使用基于网络的调查来切实收集患者报告的观点,以深入了解治疗经验和满意度。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号